MiNK Therapeutics (INKT) Competitors $7.70 +0.49 (+6.80%) Closing price 03:55 PM EasternExtended Trading$7.88 +0.18 (+2.27%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. THTX, ALEC, ACOG, ENTA, CHRS, VIGL, CGEN, PLX, RAPT, and SLNShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Theratechnologies (THTX), Alector (ALEC), Alpha Cognition (ACOG), Enanta Pharmaceuticals (ENTA), Coherus BioSciences (CHRS), Vigil Neuroscience (VIGL), Compugen (CGEN), Protalix BioTherapeutics (PLX), RAPT Therapeutics (RAPT), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Theratechnologies Alector Alpha Cognition Enanta Pharmaceuticals Coherus BioSciences Vigil Neuroscience Compugen Protalix BioTherapeutics RAPT Therapeutics Silence Therapeutics Theratechnologies (NASDAQ:THTX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Is THTX or INKT more profitable? MiNK Therapeutics has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Company Net Margins Return on Equity Return on Assets Theratechnologies-3.75% N/A -4.31% MiNK Therapeutics N/A N/A -189.14% Does the MarketBeat Community believe in THTX or INKT? Theratechnologies received 14 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 77.27% of users gave MiNK Therapeutics an outperform vote while only 54.39% of users gave Theratechnologies an outperform vote. CompanyUnderperformOutperformTheratechnologiesOutperform Votes3154.39% Underperform Votes2645.61% MiNK TherapeuticsOutperform Votes1777.27% Underperform Votes522.73% Which has stronger valuation and earnings, THTX or INKT? MiNK Therapeutics has lower revenue, but higher earnings than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$88.67M1.32-$23.96M-$0.08-31.88MiNK TherapeuticsN/AN/A-$22.46M-$2.52-3.06 Does the media favor THTX or INKT? In the previous week, MiNK Therapeutics had 11 more articles in the media than Theratechnologies. MarketBeat recorded 11 mentions for MiNK Therapeutics and 0 mentions for Theratechnologies. Theratechnologies' average media sentiment score of 0.00 beat MiNK Therapeutics' score of -0.50 indicating that Theratechnologies is being referred to more favorably in the media. Company Overall Sentiment Theratechnologies Neutral MiNK Therapeutics Neutral Do institutionals & insiders have more ownership in THTX or INKT? 2.9% of MiNK Therapeutics shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, THTX or INKT? Theratechnologies has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Do analysts recommend THTX or INKT? MiNK Therapeutics has a consensus price target of $37.50, indicating a potential upside of 387.01%. Given MiNK Therapeutics' higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMiNK Therapeutics beats Theratechnologies on 9 of the 17 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.69M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-1.9730.5026.8419.71Price / SalesN/A400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book-1.473.286.794.50Net Income-$22.46M-$72.17M$3.23B$248.18M7 Day Performance2.67%4.28%4.07%1.14%1 Month Performance6.06%7.62%12.52%15.20%1 Year Performance-22.22%-28.15%16.83%6.56% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.6544 of 5 stars$7.70+6.8%$37.50+387.0%-26.1%$30.69MN/A-1.9730Earnings ReportAnalyst RevisionGap UpTHTXTheratechnologiesN/A$2.61-0.4%N/A+108.8%$120.01M$88.67M-26.10140Gap DownALECAlector3.7824 of 5 stars$1.20+2.6%$4.00+233.3%-74.7%$119.99M$88.34M-0.71270News CoveragePositive NewsGap DownACOGAlpha Cognition1.6757 of 5 stars$7.45+0.3%$20.00+168.5%N/A$119.35MN/A-2.91N/AEarnings ReportENTAEnanta Pharmaceuticals3.8125 of 5 stars$5.55+5.3%$17.25+210.8%-51.3%$118.40M$66.59M-1.12160CHRSCoherus BioSciences3.7165 of 5 stars$1.02+5.3%$5.26+415.9%-60.8%$118.24M$266.96M-12.75330News CoverageAnalyst DowngradeVIGLVigil Neuroscience3.7214 of 5 stars$2.53+4.5%$16.25+542.3%-28.9%$118.08MN/A-1.2340Positive NewsTrading HaltedCGENCompugen1.7391 of 5 stars$1.32+4.8%$4.00+203.0%-19.0%$117.79M$27.86M66.0070News CoverageEarnings ReportAnalyst RevisionPLXProtalix BioTherapeutics2.193 of 5 stars$1.46-15.1%$15.00+927.4%+43.3%$116.10M$53.40M-11.23200Gap UpHigh Trading VolumeRAPTRAPT Therapeutics4.3849 of 5 stars$0.88+16.6%$4.00+355.2%-75.9%$116.01M$1.53M-0.3280Positive NewsGap DownSLNSilence Therapeutics3.5301 of 5 stars$3.83+3.5%$33.83+783.4%-78.0%$114.63M$43.26M-2.44100Positive News Related Companies and Tools Related Companies Theratechnologies Competitors Alector Competitors Alpha Cognition Competitors Enanta Pharmaceuticals Competitors Coherus BioSciences Competitors Vigil Neuroscience Competitors Compugen Competitors Protalix BioTherapeutics Competitors RAPT Therapeutics Competitors Silence Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INKT Stock Free INKT Stock Alerts